Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,324 across all filing types
Latest filing 2026-06-04 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 90% confidence The document is a brief announcement titled “Financial calendar” listing upcoming report and meeting dates (half-yearly report, AGM, quarterly report). It does not contain any substantive financial data itself but simply schedules future reports. This matches the definition of a Report Publication Announcement (RPA), which signals the timing or release of company reports.
2026-06-04 English
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics - Attachment: Vesica_Health_Acquisition_presentation.pdf
Investor Presentation Classification · 93% confidence The document is structured as a slide deck with title slides, legal disclaimers, forward-looking statements, transaction overview, strategic rationale, financial terms, and product/technology details. It is clearly a corporate presentation aimed at investors summarizing an acquisition and company strategy, not a formal financial report or regulatory notice. This matches the definition of an Investor Presentation (Code: IP).
2026-06-04 English
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics - Attachment: Release.pdf
M&A Activity Classification · 91% confidence The document is a corporate press release announcing and detailing the completion of Photocure ASA’s acquisition of Vesica Health Inc., including transaction terms, strategic rationale, financing structure, and related advisers. It is clearly an M&A announcement rather than a regulatory report or financial statement. Therefore, it falls under the M&A Activity category.
2026-06-04 English
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
M&A Activity Classification · 95% confidence The document is a corporate press release announcing Photocure ASA’s acquisition of Vesica Health, detailing transaction terms, strategic rationale, financing, and forward guidance. This is clearly an M&A announcement rather than an earnings release, capital raise, or other report. It fits the definition of ‘Announcements and documents related to merger proposals or takeover bids’ (Code: TAR).
2026-06-04 English
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study - Attachment: Release.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the presentation of clinical study abstracts at a scientific congress. It contains no financial results, no regulatory report attachments, no earnings figures, no board changes, no M&A or legal notices. It does not qualify as an Annual Report, Interim Report, Earnings Release, Investor Presentation, or any of the specific financial/transaction filings. As a general corporate announcement not fitting other categories, it falls under the fallback “Regulatory Filings” category (RNS).
2026-05-18 English
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing research abstracts presented at a medical conference (AUA 2026). It contains no financial statements, no earnings figures, no proxy materials, no management or board changes, and is not an investor slide deck. It is therefore a general announcement and falls under the fallback category “Regulatory Filings” (RNS).
2026-05-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.